Your Global Leader in Stem Cell Market Research
Since the discovery of induced pluripotent stem cells (iPSCs) in 2006, a large and diverse market for iPSC research tools has emerged. Included below is a ten-year history of iPSC grants (source: RePORT.NIH.gov), clinical trials (source: ClinicalTrials.gov), and scientific publications (source: PubMed.gov).
Both graphs below reveal the iPSC market is expanding. [Read more…]
MELBOURNE, Australia, Feb. 27, 2018 — Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP) is pleased to announce that the Primary Evaluation Period has been completed for the first cohort of patients in the clinical trial of its lead Cymerus™ mesenchymal stem cell (MSC) product CYP-001, for the treatment of steroid-resistant graft versus host disease (GvHD). [Read more…]
FUJIFILM Corporation and Takeda Pharmaceutical have announced they will partner to develop regenerative therapies using iPS cell-derived cardiomyocytes produced by Fujfilm’s subsidiary, Cellular Dynamics International (CDI).
“We are delighted to initiate this partnership applying practical use of our iPSC-derived cardiac cells with Takeda, which has abundant experience in drug development and clinical trials. In addition to establishing new treatment methods for patients with heart disease, Fujifilm and Takeda will contribute to the elevation of regenerative medication business to the industrial stage by applying our engineering technologies to manufacture high-quality cells safely and efficiently.”
At its core, the partnership will align manufacturing technology possessed by Cellular Dynamics International, an affiliate company of Fujifilm, with Takeda’s iPSC expertise and research to be conducted by the Center for iPS Cell Research and Application (CiRA) at Kyoto University. Together, these synergies will support pre-clinical and clinical studies for regenerative medicines that will address unmet cardiac needs, with a focus on heart failure. [Read more…]
Australian stem cell company, Cynata Therapeutics has released exciting early results from its ongoing clinical trial in the UK utilizing an iPS cell-derived mesenchymal stem cell (MSC) therapeutic product. [Read more…]
MADISON, Wis., Dec. 27, 2017— Cellular Dynamics International (CDI), a FUJIFILM company, the leading developer and manufacturer of human induced pluripotent stem cells (iPSCs) and differentiated tissue-specific iPSC-cells, announced that its iCell® Cardiomyocytes were launched into space via SpaceX’s 13th commercial resupply services mission to the International Space Station on Dec.15, 2017. The purpose of the scientific research project utilizing CDI’s iCell Cardiomyocytes in space is to validate the function of NASA’s new Bioculture System for automated cell culture on the International Space Station and to study human cardiac cell function in microgravity. [Read more…]
